
Johnson & Johnson
JNJ 195.93 (0.75%) 1.47
Health Care
Pharmaceuticals
Quality Checklist 6/8
5Y Shares Out Change < 0%
ROIC > 10%
Debt/Equity < 1
Current Ratio > 1
Net Margin > 10%
Est. EPS Growth > 5%
Quick Ratio > 1
Past Net Income CAGR > 0%
0.0%of Portfolio
My holdings
Day change:
Total change:
Shares:Cost basis:
Market cap: $472.05(B)
EV: $503.93(B)
Total Equity: $79.28(B)
Earnings date: Jan-21-2026
P/E: 18.79
Forward P/E: 18.04
P/FCF: 24.07
P/S: 5.12
P/B: 5.95
EPS: $10.4
EPS (fwd): $10.9
FCF/share: $8.1
Revenue/share: $38.3
Book value/share: $33.0
ROIC: 21.7%
ROA: 13.5%
ROE: 33.6%
Debt/Equity: 0.58
Current Ratio: 1.10
Gross margin: 68.3%
Operating margin: 26.2%
Net margin: 27.3%
Dividend/share: $5.1
Div. yield: 2.59%
JNJ Valuation & Price Targets
Current Price
$196
Favorite Valuation Methods
More Valuation Methods
DCF (simple)
N/A
N/A
DCF (exit mult.)
N/A
N/A
DDM
N/A
N/A
EPS growth
N/A
N/A
Revenue growth
N/A
N/A
Peter Lynch FV
N/A
N/A
Graham No.
N/A
N/A
PEvaluation
21% overvalued
Low
$117
Mid
$155
High
$194
Current price
$196
Fair P/E
Margin of safety
EPS
Market Model
Economic moat: Wide
EPS Estimates
| Low | Avg | High | # | |
| FY+1 | 10.8 | 10.9 | 11.0 | 25 |
| FY+2 | 11.1 | 11.5 | 11.9 | 26 |
| FY+3 | 11.7 | 12.4 | 13.3 | 21 |
| FY+4 | 12.7 | 13.2 | 14.4 | 8 |
| FY+5 | 13.2 | 14.3 | 15.5 | 7 |
Analyst Price Targets
4% undervalued
Low
$155
Mid
$205
High
$230
Current price
$196
Analyst Recommendations
2-stage DCF
First Stage Duration: 5 Years | |
| Starting Free Cash Flow | |
First Stage Growth Rate | |
LowMidHigh | |
Terminal Growth Rate | |
LowMidHigh | |
| Discount Rate | |
Discounted Cash Flow
Forecast years: 5 Years | |
Terminal Growth Rate | |
LowMidHigh | |
| Discount Rate | |
Free cash flow estimates:
Discounted Cash Flow (exit mult.)
Forecast years: 5 Years | |
Exit FCF Multiple | |
LowMidHigh | |
| Discount Rate | |
Free cash flow estimates:
Dividend Discount Model
| Annual Dividend | |
First Stage Length (Years): 0 Years | |
| First Stage Growth Rate | |
| Final Growth Rate | |
| Discount Rate | |
EPS Growth
Forecast years: 5 Years | |
| Starting EPS | |
EPS Growth Rate | |
LowMidHigh | |
Final P/E | |
LowMidHigh | |
| Discount Rate | |
Revenue Growth Valuation
Forecast Years: 10 Years | |
| Base Revenue | |
Revenue Growth Rate | |
LowMidHigh | |
Final Net Margin | |
LowMidHigh | |
Final P/E Ratio | |
LowMidHigh | |
| Discount Rate | |
Peter Lynch Fair Value
| Earnings Per Share | |
| Growth Rate |
Graham Formula
| Earnings Per Share | |
| EPS Growth (7-10 years) | |
| Government Bond Rate |
